Hematopoietic Stem Cell Transplantation for MDS

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2010 Apr 3

PMID 20359634

Citations 13

Authors

Matthias Bartenstein

H Joachim Deeg

Affiliations

Soon will be listed here.

Abstract

Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for patients with myelodysplastic syndromes (MDS). However, as the majority of patients with MDS are in the seventh or eighth decade of life, conventional transplant regimens have been used only infrequently, and only with the development of reduced-intensity conditioning has transplantation been applied more broadly to older patients. Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be expected to be cured of their disease and survive long term. However, posttransplant relapse and graft-versus-host disease (GVHD) remain problems and further investigations are needed.

Citing Articles

Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study.

Benyahia S, Kahlon S, Paul S, Aboul-Nasr Y, Harvey K, Patel M Cureus. 2025; 17(2):e78491.

PMID: 40051959 PMC: 11884420. DOI: 10.7759/cureus.78491.

Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms.

Oliva E, Guo S, Lord-Bessen J, Yucel A, Latagliata R, Breccia M Front Oncol. 2025; 15:1507854.

PMID: 39990686 PMC: 11842348. DOI: 10.3389/fonc.2025.1507854.

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle.

Wang X, Yuan L, Lu B, Lin D, Xu X Exp Ther Med. 2023; 26(6):574.

PMID: 38023359 PMC: 10652243. DOI: 10.3892/etm.2023.12274.

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.

Yang G, Wang X, Huang S, Huang R, Wei J, Wang X Front Immunol. 2022; 13:1034438.

PMID: 36268012 PMC: 9577610. DOI: 10.3389/fimmu.2022.1034438.

OMIP-080: 29-Color flow cytometry panel for comprehensive evaluation of NK and T cells reconstitution after hematopoietic stem cells transplantation.

Vanikova S, Koladiya A, Musil J Cytometry A. 2021; 101(1):21-26.

PMID: 34693626 PMC: 9298022. DOI: 10.1002/cyto.a.24510.

References

Rocha V, Locatelli F . Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2007; 41(2):207-14. DOI: 10.1038/sj.bmt.1705963. View

Gattermann N . The treatment of secondary hemochromatosis. Dtsch Arztebl Int. 2009; 106(30):499-504, I. PMC: 2735704. DOI: 10.3238/arztebl.2009.0499. View

Scott B, Storer B, Loken M, Storb R, Appelbaum F, Deeg H . Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2004; 11(1):65-73. DOI: 10.1016/j.bbmt.2004.10.001. View

Armand P, Deeg H, Kim H, Lee H, Armistead P, de Lima M . Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2009; 45(5):877-85. PMC: 2868955. DOI: 10.1038/bmt.2009.253. View

de Witte T, Oosterveld M, Muus P . Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev. 2006; 21(1):49-59. DOI: 10.1016/j.blre.2006.03.002. View

Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y . Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005; 19(3):396-401. DOI: 10.1038/sj.leu.2403640. View

de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C . Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104(3):865-72. DOI: 10.1182/blood-2003-11-3750. View

Oliansky D, Antin J, Bennett J, Deeg H, Engelhardt C, Heptinstall K . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009; 15(2):137-72. DOI: 10.1016/j.bbmt.2008.12.003. View

Karanes C, Nelson G, Chitphakdithai P, Agura E, Ballen K, Bolan C . Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008; 14(9 Suppl):8-15. DOI: 10.1016/j.bbmt.2008.06.006. View

10.

Maris M, Sandmaier B, Storer B, Chauncey T, Stuart M, Maziarz R . Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004; 104(12):3535-42. DOI: 10.1182/blood-2004-06-2275. View

11.

de Lima M, Giralt S . Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol. 2006; 43(2):107-17. DOI: 10.1053/j.seminhematol.2006.01.004. View

12.

de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M . Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and.... Leukemia. 1995; 9(11):1805-11. View

13.

Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M . The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009; 23(6):1131-8. DOI: 10.1038/leu.2009.1. View

14.

de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J . Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol. 2009; 146(6):627-36. DOI: 10.1111/j.1365-2141.2009.07809.x. View

15.

Cazzola M, Della Porta M, Malcovati L . Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008; :166-75. DOI: 10.1182/asheducation-2008.1.166. View

16.

Sierra J, Perez W, Rozman C, Carreras E, Klein J, Rizzo J . Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002; 100(6):1997-2004. View

17.

Eapen M, Logan B, Confer D, Haagenson M, Wagner J, Weisdorf D . Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007; 13(12):1461-8. PMC: 2267869. DOI: 10.1016/j.bbmt.2007.08.006. View

18.

Sucak G, Yegin Z, Ozkurt Z, Aki S, Karakan T, Akyol G . The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated?. Bone Marrow Transplant. 2008; 42(7):461-7. DOI: 10.1038/bmt.2008.193. View

19.

Diez-Campelo M, Perez-Simon J, Perez J, Alcoceba M, Richtmon J, Vidriales B . Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol. 2009; 84(3):149-52. DOI: 10.1002/ajh.21340. View

20.

Chang C, Storer B, Scott B, Bryant E, Shulman H, Flowers M . Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent.... Blood. 2007; 110(4):1379-87. PMC: 1939908. DOI: 10.1182/blood-2007-02-076307. View